Search | Clinical Trials Finder

Conditions: Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions: Positive airway pressure, NIPPV and /or oxygen; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 89 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Questionnaire Administration, Ropeginterferon Alfa-2B; Procedure · Other · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions: Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions: Rasburicase (SR29142), Allopurinol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: ascorbic acid, arsenic trioxide, dexamethasone, thalidomide; Dietary Supplement · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions: Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
Interventions: Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: COPD, OSA
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Spirometry, ACOS clinical questionnaire; Procedure · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 12
States / cities: Newport Beach, California • Upland, California • Sunset, Louisiana + 9 more

Conditions: Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
Interventions: Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York

Conditions: Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions: bi-level positive pressure non invasive ventilation, Oxygen gas; Device · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Interventions: Peer support, Online platform, Respiratory Therapist support; Other
Lead sponsor: COPD Foundation; Other
Eligibility: 40 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib, Ultrasound Imaging; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions: PRT2527, Zanubrutinib, Venetoclax; Drug
Lead sponsor: Prelude Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more

Conditions: Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, Overlap Syndrome
Interventions: Bipap procedure; Procedure
Lead sponsor: United States Air Force; Federal
Eligibility: 35 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Wpafb, Ohio

Conditions: Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Interventions: Screening; Other
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • Walnut Creek, California + 18 more

Conditions: Chronic Obstructive Airway Disease
Interventions: Bi-level positive airway pressure (BPAP), Oxygen, CPAP; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: MDS/MPN
Interventions: ASTX727, Itacitinib, Ruxolitinib; Drug
Lead sponsor: Michael Savona; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema, Asthma-COPD Overlap Syndrome
Interventions: E-Cigarette, Financial Incentives; Other · Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Obstructive Sleep Apnea
Interventions: Sleep and pulmonary physiologic measurements; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions: Luspatercept; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 155
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more

Conditions: Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions: Canakinumab (ACZ885); Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more

Conditions: Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Interventions: CPET; Diagnostic Test
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Monitoring and Peer Support to Improve Treatment Adherence and Outcomes

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Continuous Positive Airway Pressure Versus Noninvasive Ventilation in Patients With Overlap Syndrome

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes

Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA

Connect® Myeloid Disease Registry

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome